drugset / Trial / NCT01281917
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 2
Completed
40 enrolled
University of Wisconsin, Madison
Millennium Pharmaceuticals, Inc. · collabNational Cancer Institute (NCI) · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and temsirolimus for renal cell carcinoma) but are not currently approved in combination for B-cell non-Hodgkin lymphoma. The investigators are trying to find out if giving these 2 drugs together will improve the period of time that the patient's cancer is stopped or slowed from growing and causing symptoms.
Timeline
- Start
- 2011-02
- Primary completion
- 2013-10
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | — |
| Subject | Temsirolimus | Small molecule | 25 mg | Intravenous |